Timothy Coughlin
CIK 1376043 · Chief Financial Officer · last filed 2026-06-16
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$30.29M
Companies
8
Total Filings
86
Lifetime Open-Market Net
-$13.49M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| TVTX | Director | 66,250 | $55.91 | $3.70M | -$1.27M | 9 | 2026-06-16 |
| VIR | Director | 8,000 | $8.85 | $70.8K | $0 | 1 | 2026-06-10 |
| ADCT | Director | 72,400 | $1.11 | $80.4K | $0 | 2 | 2026-06-03 |
| ATYR | Director | — | $0.49 | — | $0 | 1 | 2026-05-13 |
| LIFE | Director | 56,000 | $18.80 | $1.05M | $87.5K | 12 | 2025-05-02 |
| FATE | Director | 66,282 | $2.32 | $153.8K | $117.2K | 12 | 2024-06-11 |
| Travere Therapeutics, Inc. (RTRX) Delisted | Director | 32,000 | — | — | $0 | 6 | 2020-05-19 |
| NBIX | Chief Financial Officer | 137,961 | $182.83 | $25.22M | -$12.42M | 40 | 2017-02-08 |
Recent Filings · Page 2 of 9
86 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-06-05 | ADCT | Grant (A) | +40,000 | $0 | EDGAR |
| 2025-05-16 | TVTX | Grant (A) | +6,500 | $0 | EDGAR |
| 2025-05-02 | LIFE | Grant (A) | — | $0 | EDGAR |
| 2024-06-11 | FATE | Grant (A) | — | $0 | EDGAR |
| 2024-06-03 | LIFE | Buy (P) | +50,000 | $87.5K | EDGAR |
| 2024-05-23 | LIFE | Grant (A) | — | $0 | EDGAR |
| 2024-05-10 | TVTX | Grant (A) | +6,500 | $0 | EDGAR |
| 2023-06-07 | FATE | Grant (A) | — | $0 | EDGAR |
| 2023-05-19 | LIFE | Mixed | — | $0 | EDGAR |
| 2023-05-19 | TVTX | Grant (A) | +4,500 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.